The ovarian cancer drugs market will register a CAGR of over 22% by 2023

Wednesday, February 13, 2019 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Feb. 12, 2019 /PRNewswire/ -- About this marketOvarian cancer is the second most common gynecologic cancer,

and the incidence of the disease has been increasing. The incidence of ovarian cancer increases with age, mainly due to the cell DNA damage associated with age as a result of biological processes or due to the exposure to risk factors. In terms of the
incidence rate, ovarian cancer is the eighth-most commonly occurring malignancy in women and the eighteenth-most common cancer overall. Thus, the increase in the incidence of ovarian cancer is expected to drive the growth of the global ovarian cancer drugs market during the forecast period. Technavio's analysts have predicted that the ovarian cancer drugs market will register a CAGR of over 22% by 2023.Read the full report: https://www.reportlinker.com/p05734236 Market OverviewIncreasing awareness of ovarian cancerThe increasing awareness of ovarian cancer among physicians and patients is expected to drive the growth of the market during the forecast period. This has led to increased awareness among healthcare workers regarding the symptoms of ovarian cancer and the options to manage the disease.High cost of treatmentThe treatment of ovarian cancer is costly and imposes a high economic burden on the national healthcare system and on individuals. Hence, even though cost-effective oral chemotherapy drugs are available for the treatment of ovarian cancer often they are not offered to Medicare patients due to the above regulation and patients need to spend significant out-of-pocket costs. Hence, the cost of the treatment is a significant challenge in the market.For the detailed list of factors that will drive and challenge the growth of the ovarian cancer drugs market during the 2019-2023, view our report.Competitive LandscapeThe market appears to be moderately fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.Read the full report: https://www.reportlinker.com/p05734236 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-ovarian-cancer-drugs-market-will-register-a-cagr-of-over-22-by-2023-300794155.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store